Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.
This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight key trends and share some of the biggest changes at the top and bottom of the rankings year over year.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
A closer look at 2023's top biopharma deals and what lies ahead
Winning formulas for the best biotech and drug names
[Sponsored] What does the future of specialist distribution look like?
Deep dive: Biopharma layoffs in Q1
The unrecognized threat of PAD
The top money raisers in biotech
A closer look at European biotech investment in 2024
Inclusivity in psoriasis trials with Takeda
Fierce Medtech's Fierce 15
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success
CAR-T boxed warnings: What comes next?
Breaking down Eli Lilly’s ESG formula
Gene editing's next act
The most anticipated drug launches of 2024
[Sponsored] Turning information into outcomes with MedThink Communications
[Sponsored] Talking technology and collaboration with Cytiva
Navigating the future of medical AI
Closing the $1 trillion women’s health gap
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast
Bloomberg Surveillance